Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20821033 | 0.92 | IDO1 (0.51) | PNMTHTR2AHTR2BHTR2CDAO | |
| SCHEMBL22922590 | 0.91 | IDO1 (0.43) | PNMTHTR2AHTR2BHTR2CDAO | |
| SCHEMBL20821032 | 0.87 | SLC7A5 (0.50) | HTR2AHTR2BHTR2CRIPK1 | |
| SCHEMBL7929105 | 0.85 | PNMT (0.50) | PNMTHTR2AHTR2BHTR2CDAO | |
| SCHEMBL6700680 | 0.83 | PNMT (0.53) | PNMTHTR2AHTR2BHTR2CDAO | |
| SCHEMBL1213326 | 0.82 | EPHX1 (0.49) | PNMTHTR2AHTR2BHTR2CDAO | |
| SCHEMBL10274869 | 0.81 | PNMT (0.53) | PNMTHTR2AHTR2BHTR2CDAO | |
| SCHEMBL25894263 | 0.81 | PNMT (0.53) | PNMTHTR2AHTR2BHTR2CDAO | |
| SCHEMBL24779791 | 0.81 | PNMT (0.53) | PNMTHTR2AHTR2BHTR2CDAO | |
| SCHEMBL21323231 | 0.80 | HTR2A (0.44) | PNMTHTR2AHTR2BHTR2CDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | PNMT 4566/4885HTR2A 1988/4885HTR2B 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.